Genetic risk factors for type 1 diabetes

The Lancet

Volumn 387, Issue 10035, 2016, Pages 2331-2339

  Pociot, Flemming ^a   Lernmark, Åke ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNE DISEASE; DIABETOGENESIS; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; THEORY; ADOLESCENT; ADULT; AGED; CHILD; DIABETES MELLITUS; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HAPLOTYPE; HUMAN GENOME; IMMUNOLOGY; INFANT; MIDDLE AGED; NEWBORN; PANCREAS ISLET BETA CELL; PRESCHOOL CHILD; RISK FACTOR; YOUNG ADULT;

AUTOANTIBODY; HLA ANTIGEN; RNA;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HAPLOTYPES; HLA ANTIGENS; HUMANS; INFANT; INFANT, NEWBORN; INSULIN-SECRETING CELLS; MIDDLE AGED; RISK FACTORS; RNA; YOUNG ADULT;

EID: 84975920751     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30582-7     Document Type: Review

References (56)

1. 1 Sherwin, R, Jastreboff, AM, Year in diabetes 2012: The diabetes tsunami. J Clin Endocrinol Metab 97 (2012), 4293–4301.
2. 2 Irvine, WJ, Sawers, JS, Feek, CM, Prescott, RJ, Duncan, LJ, The value of islet cell antibody in predicting secondary failure of oral hypoglycaemic agent therapy in diabetes mellitus. J Clin Lab Immunol 2 (1979), 23–26.
3. 3 Tuomi, T, Groop, LC, Zimmet, PZ, Rowley, MJ, Knowles, W, Mackay, IR, Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42 (1993), 359–362.
4. 4 Palmer, JP, Hampe, CS, Chiu, H, Goel, A, Brooks-Worrell, BM, Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age?. Diabetes 54:suppl 2 (2005), S62–S67.
5. 5 Leslie, RD, Palmer, J, Schloot, NC, Lernmark, A, Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. Diabetologia 59 (2016), 13–20.
6. 6 Ziegler, AG, Rewers, M, Simell, O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309 (2013), 2473–2479.
7. 7 Krischer, JP, Lynch, KF, Schatz, DA, et al. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia 58 (2015), 980–987.
8. 8 Ilonen, J, Hammais, A, Laine, AP, et al. Patterns of beta-cell autoantibody appearance and genetic associations during the first years of life. Diabetes 62 (2013), 3636–3640.
9. 9 Couper, JJ, Environmental triggers of type 1 diabetes. J Paediatr Child Health 37 (2001), 218–220.
10. 10 Ziegler, AG, Hillebrand, B, Rabl, W, et al. On the appearance of islet associated autoimmunity in offspring of diabetic mothers: a prospective study from birth. Diabetologia 36 (1993), 402–408.
11. 11 Sanjeevi, CB, Lybrand, TP, DeWeese, C, et al. Polymorphic amino acid variations in HLA-DQ are associated with systematic physical property changes and occurrence of IDDM. Members of the Swedish Childhood Diabetes Study. Diabetes 44 (1995), 125–131.
12. 12 Graham, J, Hagopian, WA, Kockum, I, et al. Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes. Diabetes 51 (2002), 1346–1355.
13. 13 Rewers, M, Bugawan, TL, Norris, JM, et al. Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY). Diabetologia 39 (1996), 807–812.
14. 14 Larsson, HE, Hansson, G, Carlsson, A, et al. Children developing type 1 diabetes before 6 years of age have increased linear growth independent of HLA genotypes. Diabetologia 51 (2008), 1623–1630.
15. 15 Carmichael, SK, Johnson, SB, Baughcum, A, et al. Prospective assessment in newborns of diabetes autoimmunity (PANDA): maternal understanding of infant diabetes risk. Genet Med 5 (2003), 77–83.
16. 16 Wion, E, Brantley, M, Stevens, J, et al. Population-wide infant screening for HLA-based type 1 diabetes risk via dried blood spots from the public health infrastructure. Ann N Y Acad Sci 1005 (2003), 400–403.
17. 17 Ilonen, J, Simell, O, Knip, M, Akerblom, HK, Screening for genetic IDDM risk and prevention trials in infancy. Diabetes Metab Rev, 14, 1998, 188.
18. 18 Ilonen, J, Reijonen, H, Knip, M, Simell, O, Population-based genetic screening for IDDM susceptibility as a source of HLA-genotyped control subjects. Diabetologia, 39, 1996, 123.
19. 19 Insel, RA, Dunne, JL, Atkinson, MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38 (2015), 1964–1974.
20. 20 Knip, M, Kukko, M, Kulmala, P, et al. Humoral beta-cell autoimmunity in relation to HLA-defined disease susceptibility in preclinical and clinical type 1 diabetes. Am J Med Genet 115 (2002), 48–54.
21. 21 Ziegler, R, Alper, CA, Awdeh, ZL, et al. Specific association of HLA-DR4 with increased prevalence and level of insulin autoantibodies in first-degree relatives of patients with type I diabetes. Diabetes 40 (1991), 709–714.
22. 22 Zhao, LP, Alshiekh, S, Carlsson, A, et al. Next generation sequencing reveals that HLA-DRB3, -DRB4 and -DRB5 may be associated with islet autoantibodies and risk for childhood type 1 diabetes. Diabetes 65 (2016), 710–718.
23. 23 Erlich, HA, Valdes, AM, McDevitt, SL, et al. Next generation sequencing reveals the association of DRB3*02:02 with type 1 diabetes. Diabetes 62 (2013), 2618–2622.
24. 24 Torn, C, Hadley, D, Lee, HS, et al. Role of type 1 diabetes-associated SNPs on risk of autoantibody positivity in the TEDDY study. Diabetes 64 (2015), 1818–1829.
25. 25 Hagopian, WA, Erlich, H, Lernmark, A, et al. The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants. Pediatr Diabetes 12 (2011), 733–743.
26. 26 Ziegler, AG, Hummel, M, Schenker, M, Bonifacio, E, Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48 (1999), 460–468.
27. 27 Nejentsev, S, Sjoroos, M, Soukka, T, et al. Population-based genetic screening for the estimation of Type 1 diabetes mellitus risk in Finland: selective genotyping of markers in the HLA-DQB1, HLA-DQA1 and HLA-DRB1 loci. Diabet Med 16 (1999), 985–992.
28. 28 Bonifacio, E, Ziegler, AG, Klingensmith, G, et al. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. JAMA 313 (2015), 1541–1549.
29. 29 Barrett, JC, Clayton, DG, Concannon, P, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 41 (2009), 703–707.
30. 30 Onengut-Gumuscu, S, Chen, WM, Burren, O, et al. Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. Nat Genet 47 (2015), 381–386.
31. 31 Clayton, DG, Prediction and interaction in complex disease genetics: experience in type 1 diabetes. PLoS Genet, 5, 2009, e1000540.
32. 32 Groop, L, Pociot, F, Genetics of diabetes—are we missing the genes or the disease?. Mol Cell Endocinol 382 (2014), 726–739.
33. 33 Boyle, AP, Hong, EL, Hariharan, M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 22 (2012), 1790–1797.
34. 34 Mirza, AH, Kaur, S, Brorsson, CA, Pociot, F, Effects of GWAS-associated genetic variants on lncRNAs within IBD and T1D candidate loci. PLoS One, 9, 2014, e105723.
35. 35 Hunter, CA, New IL-12 family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Genet 7 (2005), 521–531.
36. 36 Meka, RR, Venkatesha, SH, Dudics, S, Acharya, B, Moudgil, KD, IL-27-induced modulation of autoimmunity and its therapeutic potential. Autoimmun Rev 14 (2015), 1131–1141.
37. 37 Fujimoto, H, Hirase, T, Miyazaki, Y, et al. IL-27 inhibits hyperglycaemia and pancreatic islet inflammation induced by streptozotocin in mice. Am J Pathol 179 (2011), 2327–2336.
38. 38 Wang, R, Han, G, Wang, J, et al. The pathogenic role of interleukin-27 in autoimmune diabetes. Cellular and molecular life sciences. Cell Mol Life Sci 65 (2008), 3851–3860.
39. 39 Doerflinger, M, Glab, JA, Puthalakath, H, BH3-only proteins: a 20-year stock-take. FEBS J 282 (2015), 1006–1016.
40. 40 Gurzov, EN, Eizirik, DL, Bcl-2 proteins in diabetes: mitochondrial pathways of beta-cell death and dysfunction. Trends Cell Biol 21 (2011), 424–431.
41. 41 Danial, NN, Walensky, LD, Zhang, CY, et al. Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat Med 14 (2008), 144–153.
42. 42 Wei, P, Shi, M, Barnum, S, Cho, H, Carlson, T, Fraser, JD, Effects of glucokinase activators GKA50 and LY2121260 on proliferation and apoptosis in pancreatic INS-1 beta cells. Diabetologia 52 (2009), 2142–2150.
43. 43 Gonzalez-Amaro, R, Cortes, JR, Sanchez-Madrid, F, Martin, P, Is CD69 an effective brake to control inflammatory diseases?. Trends Mol Med 19 (2013), 625–632.
44. 44 Fløyel, T, Brorsson, C, Nielsen, LB, et al. CTSH regulates beta-cell function and disease progression in newly diagnosed type 1 diabetes patients. Proc Natl Acad Sci USA 111 (2014), 10305–10310.
45. 45 Kaur, S, Mirza, AH, Brorsson, CA, et al. The genetic and regulatory architecture of ERBB3-type 1 diabetes susceptibility locus. Mol Cell Endocrinol 419 (2016), 83–91.
46. 46 Soleimanpour, SA, Gupta, A, Bakay, M, et al. The diabetes susceptibility gene Clec16a regulates mitophagy. Cell 157 (2014), 1577–1590.
47. 47 Zouk, H, D'Hennezel, E, Du, X, Ounissi-Benkalha, H, Piccirillo, CA, Polychronakos, C, Functional evaluation of the role of C-type lectin domain family 16A at the chromosome 16p13 locus. Clin Exp Immunol 175 (2014), 485–497.
48. 48 Davison, LJ, Wallace, C, Cooper, JD, et al. Long-range DNA looping and gene expression analyses identify DEXI as an autoimmune disease candidate gene. Hum Mol Genet 21 (2012), 322–333.
49. 49 Wang, H, Jin, Y, Reddy, MV, et al. Genetically dependent ERBB3 expression modulates antigen presenting cell function and type 1 diabetes risk. PLoS One, 5, 2010, e11789.
50. 50 Brorsson, CA, Pociot, F, Type 1 Diabetes Genetics Consortium. Shared genetic basis for type 1 diabetes, islet autoantibodies, and autoantibodies associated with other immune-mediated diseases in families with type 1 diabetes. Diabetes Care 38:suppl 3 (2015), S8–13.
51. 51 Torn, C, Hadley, D, Lee, HS, et al. Role of type 1 diabetes-associated SNPs on risk of autoantibody positivity in the TEDDY study. Diabetes 64 (2015), 1818–1829.
52. 52 Bunyavanich, S, Schadt, EE, Systems biology of asthma and allergic diseases: a multiscale approach. J Allergy Clin Immunol 135 (2015), 31–42.
53. 53 Stene, LC, Oikarinen, S, Hyoty, H, et al. Enterovirus infection and progression from islet autoimmunity to type 1 diabetes: the Diabetes and Autoimmunity Study in the Young (DAISY). Diabetes 59 (2010), 3174–3180.
54. 54 Mattila, TK, de Boer, A, Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus. Drugs 70 (2010), 2229–2245.
55. 55 Ahlqvist, E, van Zuydam, NR, Groop, LC, McCarthy, MI, The genetics of diabetic complications. Nat Rev Nephrol 11 (2015), 277–287.
56. 56 Parkes, M, Cortes, A, van Heel, DA, Brown, MA, Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet 14 (2013), 661–673.